pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Wegovy · news · pharmadog
← back to Wegovy
News mentioning Wegovy
176
stories
Sep 22, 26
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
Sep 22, 26
Novo’s workforce reduction climbs to 13,000 to fuel R&D work
biospace
Sep 22, 26
Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
fiercebiotech
Sep 21, 26
Novo talks up drug launches in effort to win back investors
biopharma dive
Sep 21, 26
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
Sep 21, 26
Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts
biospace
Sep 21, 26
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
Sep 21, 26
Are healthcare systems really ready for GLP-1s?
biopharma dive
Sep 18, 26
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
fiercebiotech
Sep 18, 26
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope
fiercebiotech
Sep 17, 26
Novo partners with Orbis, deepening investment in oral peptide drugs
biopharma dive
Sep 17, 26
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
Sep 16, 26
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
fiercebiotech
Sep 16, 26
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
fiercebiotech
Sep 15, 26
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
fiercebiotech
Sep 14, 26
Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand
biospace
Sep 14, 26
Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
fiercebiotech
Sep 14, 26
No more Nordisk as Novo goes it alone amid rebranding push
fiercebiotech
Sep 9, 26
Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets
biospace
Sep 9, 26
Telemedicine company offers GLP-1s for addiction
stat
Sep 8, 26
Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12
endpoints
Sep 8, 26
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
biospace
Sep 4, 26
Menarini signs $771M deal to take Gan & Lee GLP-1 to European market
fiercebiotech
Aug 28, 26
Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro
biospace
Aug 28, 26
STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and more
stat
Aug 27, 26
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
biospace
Aug 26, 26
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
biospace
Aug 25, 26
Lilly takes oral obesity race abroad with UK launch of Foundayo
biospace
Aug 24, 26
Roche commits to lean-mass preservation with Hanmi obesity deal
biopharma dive
Aug 21, 26
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
biospace
← prev
page 3 of 6
next →